Cannabics Pharmaceuticals Inc. (CNBX) 0.2700

New Post Public Reply Private Reply Replies (0) Message Board

Apr 12, 2015 at 11:02 AM

Cannabics Pharmaceuticals Inc. (CNBX) 0.2700 $CNBX

Cannabics Pharmaceuticals Inc. Engages with the Technion Institute for the Screening of Potential Anticancer Cannabinoid Compounds
PR Newswire - Mon Apr 06, 7:30AM CDT
Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) announced today that it has executed a Research Agreement with the Israel Institute of Technology (Technion) in Israel, for the screening of potential Anticancer Cannabinoid compounds.

Cannabics Pharmaceuticals Inc. Engages with the Technion Institute for Screening of Potential Anticancer Cannabinoid Compounds
ACCESSWIRE - Thu Apr 02, 6:25PM CDT
BETHESDA, MD / ACCESSWIRE / April 2, 2015 / Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) announced today that it has executed a Research Agreement with the Israel Institute of Technology (Technion) in Israel, for the screening of potential Anticancer Cannabinoid compounds.

Anorexia Nervosa Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tzf2t/anorexia_nervosa) has announced the addition of the "Anorexia Nervosa Global Clinical Trials Review, H1, 2015" report to their offering. Anorexia Nervosa Global Clinical Trials Review, H1, 2015 provides data on the Anorexia Nervosa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anorexia Nervosa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anorexia Nervosa. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Anorexia Nervosa Therapeutics Clinical Trials - Sky Growth Acquisition Corporation - Medionics International Inc - Daiichi Sankyo Company, Limited - Cannabics Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - BioGaia AB - AstraZeneca PLC - Arjun Healthcare - Anaborex, Inc. For more information visit http://www.researchandmarkets.com/research/7t...ia_nervosa
AZN: 69.91 (-0.25), BMY: 64.64 (+1.18)

48 Marijuana Stocks - A Post-Mortem: Part II
Anthony Cataldo - at Seeking Alpha - Wed Mar 04, 7:36AM CST

INSY: 57.97 (+0.06), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27)

117 Marijuana Stocks For Your Do Not 'Buy-And-Hold' List
Anthony Cataldo - at Seeking Alpha - Fri Feb 06, 10:14AM CST

GWPH: 91.32 (+0.38), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27)

99 Marijuana Stocks For Your Do Not 'Buy And Hold' List
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 6:25AM CST

GWPH: 91.32 (+0.38), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27), ICN: 21.42 (-0.02)

Marijuana Firms - Exploring N=99, Ranked By Market Capitalization
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 3:34AM CST

GWPH: 91.32 (+0.38), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27)

12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part VIII
Anthony Cataldo - at Seeking Alpha - Wed Jan 28, 6:48AM CST

GWPH: 91.32 (+0.38), DE: 89.07 (+0.62), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27)

Cannabics Pharmaceuticals engages with Mountain High Products in Colorado
PR Newswire - Thu Dec 18, 8:41AM CST
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has executed a letter of engagement with Mountain High Products in Colorado, for the manufacturing and distribution of Cannabics SR medical cannabis products in the Colorado market.

American Cannabis Company, A Delaware Corporation, Joins The List Of At Least 46 Other Marijuana Stocks
Anthony Cataldo - at Seeking Alpha - Sun Dec 07, 5:36PM CST

GWPH: 91.32 (+0.38), FULL: 3.55 (-0.03)

Cannabics Pharmaceuticals Signs IP Licensing and Collaboration Agreement in Spain
Marketwired - Thu Nov 06, 7:32AM CST
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has executed an IP Licensing and Collaboration Agreement with Kalapa Holding (Spain) for the production and distribution of CANNABICS SR medical cannabis products in the Spanish market.

Cannabics Pharmaceuticals, Inc. to Present at Cannabis Investor Webcast
ACCESSWIRE - Mon Oct 27, 7:01PM CDT
Bethesda, MD / ACCESSWIRE / October 27, 2014 / Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) will be presenting at the Cannabis Investor Webcast on Tuesday, October 28, 2014 at 11:00 AM ET.

Cannabics Pharmaceuticals Receives Cannabinoid R&D Lab Certification in Israel
Marketwired - Mon Oct 20, 8:05AM CDT
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) announced today that it has received Government Certification from the Ministry of Health in Israel for the establishment of an advanced R&D laboratory dedicated to medical research in the field of cannabinoid science.

Cannabics Pharmaceuticals, Inc. (CNBX) Attains GMP Compliance, Prepares for First Clinical Study of Cannabics SR
Marketwire - Fri Sep 26, 7:30AM CDT
Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX), a developer of advanced medical cannabis therapies, announces that it has achieved Good Manufacturing Practices (GMP) capabilities as the Company moves toward the launch of its first clinical study of Cannabics SR capsules.

Cannabics Pharmaceuticals recruits two former senior Teva Executives to its Advisory Board
Business Wire - Tue Aug 19, 2:23PM CDT
Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) announced today that the Company has made two key appointments to the Company's Advisory Board with the recent recruitment of Mr. Ika Abravanel as senior advisor in the field of operational and strategic planning, and Dr. Sigalit Ariely-Portnoy, as senior advisor in the field of regulation, validation and quality.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PeptideWorld Paves the Way for Innovative Peptide Education

The Rise of Peptide Education Imagine you're wading through a bog of health trends. That's how it feels trying to get a grip on peptide therapies these days, right? Luckily, PeptideWorld, powered by e?vita Health, is here to toss you a lifeline. They're transforming the landscape with a mission to ditch the marketing mumbo-jumbo for hard science. Their pitch?...

AVENIR GLOBAL Snaps Up Marker Collective: Bold Move

AVENIR GLOBAL Expands Its Empire In what looks like a bold stride forward, AVENIR GLOBAL's acquisition of Marker Collective ain't just some casual Sunday stroll. This is a hefty leap into the big league of communications, catapulting the Montreal-based outfit into the ranks of the world's top 15 firms by revenue. Might say it's one hell of a way to celebrate the company's...

Fluence Energy Lawsuit: Investors Face Key Deadline

Fluence Energy Under Fire Fluence Energy, Inc., ain't having the best of times, folks. If you've been keeping an eye on the stock ticker NASDAQ:FLNC, you probably felt the shiver when the news of a securities fraud class action lawsuit hit the wire. This ain't about some minor slip-up. These allegations are rocking the boat hard. What's at Stake for Investors? Here's the...

SHOPLINE's Pitch Day: 14 Brands in the Spotlight

SHOPLINE's Los Angeles Event Highlights Emerging Brands Flip the calendar back to October 1, and you'll find me soaking in the scene at the sprawling halls of SHOPLINE and Plug and Play’s latest event. This wasn’t your run-of-the-mill networking affair; it was a caffeine-fueled, adrenaline-pumping showcase of 14 up-and-coming consumer brands. Now, if there's one thing...

GovSignals Unveils New Tech for Navy Collaboration

GovSignals' Strategic Leap in Defense Collaboration Tensions and possibilities always ride high when the defense sector flirtations with groundbreaking tech, and today it's GovSignals stepping into the limelight with some never-before-seen moves. With their prototype platform under Project Roundtable, they've ditched traditional routes. Admirals at the Navy must be...

Globee® AI Awards Calls For Global Innovation Entries

Rolling Out the Red Carpet for AI Innovators Worldwide Here's a call to all the boundary-pushing eggheads tinkering with artificial intelligence. The Globee® Awards is opening its doors again for the 3rd Annual AI showdown, inviting nominations from the creative minds conjuring up AI magic across the globe. This ain't your grandma's science fair; we're talking real-world...

Brightstar's iCAP Ready Badge: A Gamble on Responsibility

Another Feather in Brightstar's Cap You might not toss 'responsible gaming standards' around in casual talk, but in the gaming biz, it's a badge of honor. Brightstar Lottery PLC (NYSE: BRSL) ain't just spinning wheels here—they've got themselves re-accredited with iCAP Ready from the National Council on Problem Gambling (NCPG). It's the stamp of approval that shows...

Changshan's Tourism Boom: 22.8% Increase Over Holiday

Changshan Grabs Attention This National Day You know, I blinked twice when I saw Changshan's tourist numbers this year. During the 2026 National Day holiday, they managed to snag 503,000 visitors. That's up by a whopping 22.8% from last year. If that doesn't grab your attention, I don't know what will. We're talking record numbers here, folks, and that's the kind of...

Taiwan's Bold Bid: From Tech Hub to Capital Magnet

Ambitious Plans Unveiled at Taiwan Weeks 2026 Forget the usual humdrum; Taiwan’s pulling no punches in its bid to become a capital powerhouse in Asia. If you'd told me years ago that Taiwan was eyeing dominance in asset management, I might've laughed. But at the 2026 Taiwan Weeks, they showed they're dead serious about it. Over 400 bigwigs and market shakers gathered,...

Mondego Bio Charges Ahead with Cancer Therapy Trials

Cracking Cancer's Code: Mondego's Bold Move Big news from Portugal today—a quiet town called Cantanhede is now the epicenter of a potential game-changer in cancer therapy. Mondego Bio, with its small-molecule innovator MB?388, is diving headfirst into a Phase 1 clinical study. If you're scratching your head about the significance, let me spell it out: this is an attempt...